Nilofer Saba Azad, MD, discusses selecting between regorafenib and TAS-102 in colorectal cancer.
Nilofer Saba Azad, MD
Advertisement
Articles by Nilofer Saba Azad, MD
Nilofer Saba Azad, MD, discusses third-line treatment options for patients with colorectal cancer.
Nilofer Saba Azad, MD, discusses future research efforts in colorectal cancer.
Nilofer Saba Azad, MD, discusses the significance of germline testing in colorectal cancer.
Nilofer Saba Azad, MD, discusses treatment considerations in right- versus left-sided colorectal cancer.
Nilofer Saba Azad, MD, discusses remaining challenges in colorectal cancer.
Advertisement
Latest Updated Articles
Dr. Azad on Treatment Considerations in Right- Versus Left-Sided CRCOctober 16th 2020
Dr. Azad on the Importance of Germline Testing in CRCOctober 19th 2020
Dr. Azad on Future Research Efforts in CRCOctober 21st 2020
Dr. Azad on Selecting Between Regorafenib and TAS-102 in CRCOctober 30th 2020
Dr. Azad on Remaining Challenges in CRCOctober 15th 2020
Dr. Azad on Third-Line Treatment Options in CRCOctober 28th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
2
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
5